Advertisement

Treatment Trials in Aging and Mild Cognitive Impairment

  • Jody Corey-BloomEmail author
Chapter
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 10)

Abstract

There are currently no FDA-approved therapies for mild cognitive impairment (MCI) as no treatment trial to date has convincingly demonstrated a significant effect on cognition or symptom progression. Whether the problem lies with the evaluated compounds, drugs previously shown to have therapeutic benefit in Alzheimer disease (AD), or the clinical trial designs themselves, remains unclear. However, future trials will likely need to use strategies to enrich for more homogeneous samples with appropriate biological characteristics at entry, define optimal treatment durations, and develop highly sensitive assessments and reliable outcomes with the power to detect change and treatment benefit in mildly impaired subjects.

Keywords

Aging Mild cognitive impairment Treatment Clinical trials 

References

  1. Aisen PS (2002) The potential of anti-inflammatory drugs for the treatment of Alzheimer’s disease. Lancet Neurol 1(5):279–284PubMedCrossRefGoogle Scholar
  2. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, Alzheimer’s Disease Cooperative Study (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289(21):2819–2826PubMedCrossRefGoogle Scholar
  3. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD, Ginkgo Evaluation of Memory (GEM) Study Investigators (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300(19):2253–2262PubMedCrossRefGoogle Scholar
  4. Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK (2009) Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 72(18):1555–1561PubMedCrossRefGoogle Scholar
  5. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R (2007) Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 6(6):501–512 Erratum in: Lancet Neurol. 2007 Oct; 6(10):849PubMedCrossRefGoogle Scholar
  6. Martin M, Clare L, Altgassen AM, Cameron MH, Zehnder F (2011) Cognition-based interventions for healthy older people and people with mild cognitive impairment. Cochrane Database Syst Rev 1:CD006220Google Scholar
  7. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, Alzheimer’s Disease Cooperative Study Group (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352(23):2379–2388PubMedCrossRefGoogle Scholar
  8. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S, Donepezil 401 Study Group (2004) Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 63(4):651–657PubMedCrossRefGoogle Scholar
  9. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon JCW, Pfeifer E, Schneider LS, Thal LJ, for the Members of the Alzheimer’s Disease Cooperative Study (1997) A two-year, double-blind, randomized multicenter trial of Selegiline and α-tocopherol in the treatment of Alzheimer’s disease. New Eng J Med 336(17):1245–1247CrossRefGoogle Scholar
  10. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA, Rofecoxib Protocol 078 study group (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30(6):1204–1215PubMedCrossRefGoogle Scholar
  11. Tsolaki M, Kounti F, Agogiatou C, Poptsi E, Bakoglidou E, Zafeiropoulou M, Soumbourou A, Nikolaidou E, Batsila G, Siambani A, Nakou S, Mouzakidis C, Tsiakiri A, Zafeiropoulos S, Karagiozi K, Messini C, Diamantidou A, Vasiloglou M (2011) Effectiveness of nonpharmacological approaches in patients with mild cognitive impairment. Neurodegener Dis 8(3):138–145PubMedCrossRefGoogle Scholar
  12. Winblad B, Jelic V (2004) Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord 18(Suppl 1):S2–S8PubMedCrossRefGoogle Scholar
  13. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS, GAL-INT-11/18 Study Group (2008) Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70(22):2024–2035PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Shiley-Marcos Alzheimer Disease Research CenterUniversity of California,San DiegoLa JollaUSA

Personalised recommendations